London Calling 2026 Technology Update

21 May 2026 -Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore-based sensing technology, presented a Technology Update at the Company’s flagship annual London Calling customer conference.

Opening London Calling 2026, Chief Executive Francis Van Parys highlighted the Company’s continued focus on customer-led platform development, strengthening the user end‐to‐end experience and supporting broader adoption in applied and regulated environments. He also underlined ongoing investment in longer-term innovation to extend platform capabilities.

At the Annual Technology Talk Lakmal Jayasinghe, Chief Scientific Officer and the team including Graham Hall, Sissel Juul, Mike Vella, Mark Bruce and Jayne Wallace, highlighted updates including:

Platform development led by customer need

• Delivering richer multiomic insight from a single platform: advances in integrated DNA, RNA and epigenetic data, including methylation, providing comprehensive insight from a single system.

• Driving continuous improvement in platform performance, including accuracy, base modifications, output and speed, with continued enhancement of unique features such as adaptive sampling. This includes the introduction of the PromethION Plus flow cell, designed to increase output with enhanced yield achieved without additional wash and reload steps. The Company also highlighted increasing use of AI-driven methods across basecalling, variant detection and downstream analysis.

• Expanding platform capability across core workflows, including transcriptomics (RNA), microbial and vaccine QC (GridION Q), and high-output sequencing (PromethION), with new chemistry and workflows shipping from May to July 2026.

Regulatory readiness

• Advancing reliability and consistency: improvements in repeatability and robust performance in production environments, enabling predictable use at scale.

• Expanding real-world deployment across routine and regulated settings.

End-to-end experience

• Simplifying workflows and reducing complexity to support broader adoption.

• Advancing integrated software platforms, including EPI2ME, for accessible and standardised data interpretation.

Longer-term innovation and platform pipeline

• Continuing investment across chemistry and hardware towards both low and high output applications, and development of multiomic capability including protein sequencing, extending the platform into new areas of biological insight.

• Showcasing a novel demonstration of peptide sequencing using an amino-acid calling for accurate protein identification.

A video replay of the Technology Talk is available on the London Calling/ Oxford Nanopore website.